A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System

Exclusion criteria

• . Phase 1 dose escalation and Phase 2 cancer treatment expansion cohorts:
• . History of any of the following ≤6 months before first dose: congestive heart failure New York Heart Association Grade III or IV, unstable angina, myocardial infarction, unstable symptomatic ischemic heart disease, severe noncompensated hypertension despite appropriate medical therapy, ongoing symptomatic cardiac arrhythmias of \>Grade 2, pulmonary embolism, or symptomatic cerebrovascular events, or any other serious cardiac condition (example, pericardial effusion or restrictive cardiomyopathy). Chronic atrial fibrillation on stable anticoagulant therapy is allowed.
• . Baseline prolongation of the QT interval with Fridericia correction method (QTcF) (example, repeated demonstration of QTcF interval \>480 milliseconds (ms), history of congenital long QT syndrome, or torsades de pointes).
• . Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of adverse events (AEs) or has compromised ability to provide written informed consent.
• . Admission or evidence of illicit drug use, drug abuse, or alcohol abuse.
• . History of autoimmune disease requiring systemic immunosuppressive therapy.
• . History of immune-related AEs related to treatment with immune checkpoint inhibitors that required treatment discontinuation.
• . History of noninfectious pneumonitis that required steroids or a history of interstitial lung disease.